The status of TP53 has been considered as a determining factor for the sensitivity of PLK1 inhibitors in combination with radiotherapy for the treatment of non-small cell lung cancer and colorectal cancer (Van den Bossche et al., 2019; Sur et al., 2009). Here, PLK1 is linked to non-small cell lung carcinoma.